Hey Jane Clinical Gaps & Limitations: What the Platform Covers (and What It Misses)

What Is Hey Jane and Is It Legitimate?

Hey Jane is a licensed telehealth platform staffed by clinicians, and the services it does offer are grounded in real clinical protocols. The platform is not a scam. The core question worth asking, though, is not whether Hey Jane is legitimate but whether it is sufficient for your full reproductive and metabolic health picture.

The company launched to address a specific and urgent problem: access to medication abortion in a post-Dobbs environment where geographic and logistical barriers have made in-clinic care difficult or impossible for millions of women. That mission is real, and the need is documented. A 2023 analysis published in JAMA found that after the Supreme Court's Dobbs decision, the number of women traveling out of state for abortion care rose sharply, and telehealth abortion services absorbed a meaningful share of the demand. Hey Jane operates squarely in that space.

What Hey Jane Prescribes

The platform's core offerings include:

• Medication abortion using mifepristone 200 mg followed by misoprostol 800 mcg buccally at 24-48 hours, the evidence-based regimen endorsed by ACOG's practice bulletin on medication abortion
• Emergency contraception, including ulipristal acetate (ella) and levonorgestrel-based options
• Hormonal birth control, primarily oral contraceptive pills and some additional methods depending on state
• STI testing and treatment, including chlamydia, gonorrhea, and some other common infections
• Urinary tract infection (UTI) treatment

What is notably absent from that list is as clinically important as what is present.

The Cash-Pay Model and Who It Excludes

Hey Jane does not bill insurance. Prices for medication abortion run approximately $249 to $349 depending on the state and service level. Birth control pricing varies by product. For a woman with strong income and no insurance coverage gaps, this is manageable. For the women who most need affordable reproductive care, the out-of-pocket requirement creates a real barrier.

Research published in Obstetrics & Gynecology has documented that financial barriers to abortion care fall disproportionately on women of lower income, women of color, and women who are already parenting. A platform that charges cash without insurance billing does not fully dissolve those barriers; it shifts them.

The Clinical Scope Problem: What Hey Jane Does Not Cover

This is where an honest assessment of Hey Jane diverges from the platform's own marketing.

Perimenopause and Menopause

Hey Jane does not offer perimenopause or menopause care. No hormone therapy prescribing, no assessment of vasomotor symptoms, no bone-health counseling, no genitourinary syndrome of menopause (GSM) management. For a woman in her mid-40s who is also navigating irregular cycles and hot flashes, Hey Jane can handle her birth control but cannot address the larger hormonal picture that birth control is now intersecting with.

This matters clinically because the perimenopausal transition changes how hormonal contraception performs and what its risks mean. The Menopause Society's 2023 position statement notes that combined hormonal contraceptives can mask the menstrual irregularity that signals perimenopause, potentially delaying the diagnosis of a transition that has bone, cardiovascular, and cognitive implications. A platform that prescribes the pill without addressing this context is providing an incomplete clinical picture for women over 40.

PCOS and Hormonal Acne

Polycystic ovary syndrome affects approximately 8 to 13 percent of women of reproductive age globally, making it one of the most common endocrine conditions in women. Hey Jane does not offer PCOS diagnosis or management. If a woman comes to Hey Jane seeking birth control because her OB-GYN mentioned her cycles are irregular, the platform will prescribe the pill without screening for or addressing the underlying hormonal condition.

PCOS management goes well beyond cycle regulation. It includes metabolic surveillance (insulin resistance, lipid panels, blood pressure), fertility counseling, and in some cases medications like metformin or GLP-1 receptor agonists. None of these fall within Hey Jane's clinical mandate.

Hormonal acne, a frequent presenting complaint linked to androgen excess in PCOS, is similarly outside the scope. A woman seeking spironolactone for acne, a common and evidence-supported off-label use, will not find that prescription at Hey Jane.

Thyroid Conditions

Postpartum thyroiditis affects approximately 5 to 10 percent of women in the first year after delivery, and autoimmune thyroid disease is significantly more prevalent in women than men across the lifespan. Hey Jane does not offer thyroid assessment or management. For a postpartum woman using Hey Jane for contraception, this is a gap worth naming explicitly.

Fertility

Hey Jane does not address fertility workup, ovulation induction, or preconception counseling. A woman who stops her Hey Jane-prescribed pill and wants to conceive has no clinical continuity within the platform. ASRM guidelines recommend preconception counseling for all women planning pregnancy, including review of medications, supplements, and underlying conditions. That guidance cannot be acted on through Hey Jane.

Endometriosis

Endometriosis affects roughly 10 percent of reproductive-age women, often causes debilitating dysmenorrhea and pelvic pain, and is frequently delayed in diagnosis by 7 to 10 years. Hey Jane does not offer endometriosis diagnosis or management. A woman whose painful periods are the reason she is seeking birth control in the first place may receive cycle suppression without any effort to identify the underlying condition.

A useful way to think about Hey Jane's scope is what we call the Reproductive Window Problem: the platform serves women well in a narrow clinical window centered on preventing or ending pregnancy and treating acute infections, but it does not support women across the full arc of reproductive life, from preconception through postpartum, perimenopause, and beyond. Most women's reproductive and hormonal health needs span that entire arc. A platform that covers only the middle leaves significant unmet need on both sides.

Pregnancy, Lactation, and Contraception: The Full Clinical Picture

Medication Abortion Safety Data

The mifepristone plus misoprostol regimen used by Hey Jane has a well-documented safety record. A Cochrane systematic review found that the combination regimen is highly effective (greater than 95 percent) and associated with low rates of serious adverse events when used up to 70 days of gestation. The FDA approved mifepristone in 2000, and the current FDA-approved regimen supports use through 70 days (10 weeks) from the last menstrual period.

Side effects are real and should be communicated clearly. They include heavy bleeding, cramping, nausea, vomiting, diarrhea, and chills. Serious complications, including infection and incomplete abortion requiring aspiration, occur in fewer than 1 percent of cases in clinical settings.

Teratogenicity Warning

Misoprostol is a pregnancy category X drug when used in doses intended to terminate pregnancy, meaning it is contraindicated in ongoing wanted pregnancies. Fetal exposure to misoprostol in failed attempted abortion has been associated with limb reduction defects and Mobius sequence in case reports and epidemiological data. This is why patient selection for gestational age accuracy matters enormously in telehealth abortion services, and why Hey Jane's intake process requires confirmation of dates and, in some cases, ultrasound documentation.

Emergency Contraception and Ongoing Contraception

Ulipristal acetate (ella), available through Hey Jane, is a selective progesterone receptor modulator with documented effectiveness up to 120 hours after unprotected sex. It should not be taken by a woman who may already be pregnant, and it can reduce the effectiveness of hormonal contraceptives started in the same cycle. FDA prescribing information for ella notes this interaction explicitly. Hey Jane's prescribing should address this transition point, though independent confirmation of whether this counseling is consistently delivered is limited.

Lactation

Mifepristone transfers into breast milk at low levels. Published pharmacokinetic data suggest minimal infant exposure when a mother pumps and discards milk for 36 to 72 hours after the mifepristone dose. Misoprostol has a very short half-life (20 to 40 minutes) and is unlikely to accumulate in milk at clinically significant levels. Women who are breastfeeding and using Hey Jane for medication abortion should receive explicit counseling on this pumping protocol.

Contraception After Medication Abortion

ACOG guidance states that ovulation can return as early as 8 days after a medication abortion, meaning contraception should be started promptly. Hey Jane does prescribe birth control in this context, which is an important feature of the platform. The follow-through on contraceptive counseling after a completed abortion is a clinical strength of the model when executed well.

Who Hey Jane Is Right For (and Who Needs More)

Reproductive-Age Women Who May Benefit

• A woman seeking medication abortion in an early gestation who lives in a state where Hey Jane operates and cannot easily access an in-person clinic
• A woman needing emergency contraception quickly and with privacy
• A woman seeking oral contraceptives without a routine in-person visit
• A woman with an acute, uncomplicated UTI or a simple STI that fits a standard telehealth treatment protocol

Women Who Need More Than Hey Jane Offers

• Perimenopausal women (typically 40 to 55): need hormonal assessment, bone density consideration, cardiovascular risk review, and sometimes menopause hormone therapy, none of which Hey Jane provides
• Women with PCOS: need metabolic workup, androgen management, fertility counseling, and potentially medications beyond standard hormonal contraception
• Postpartum women: need screening for postpartum thyroiditis, postpartum depression assessment, pelvic floor considerations, and lactation support alongside contraception
• Women trying to conceive: need preconception workup, folate counseling, medication review, and potentially fertility evaluation
• Women with endometriosis or fibroids: need imaging, specialist referral pathways, and pain management strategies that go beyond cycle suppression

A Note on the Evidence Gap

Women have been chronically underrepresented in clinical trials across nearly all therapeutic areas. In reproductive telehealth specifically, data comparing outcomes across different platforms are sparse. Hey Jane has published limited outcome data publicly. We do not have peer-reviewed, independently audited completion rates, complication rates, or follow-up adherence rates specific to Hey Jane's patient population. This is not unique to Hey Jane, but it means that clinician and patient trust in any telehealth abortion service rests substantially on the quality of the underlying clinical protocol rather than the platform's proprietary outcomes data.

As ACOG's telehealth guidance notes, telehealth reproductive services should meet the same clinical standards as in-person care, including appropriate informed consent, follow-up protocols, and complication management pathways. Whether any specific platform consistently achieves this standard is difficult for an external reviewer to verify without access to internal audit data.

Hey Jane vs. Alternatives: A Practical Comparison

No telehealth platform covers all of women's health comprehensively, but the gaps vary significantly by platform and are worth mapping.

| Service Area | Hey Jane | Midi Health | Wisp | Planned Parenthood Direct | |---|---|---|---|---| | Medication abortion | Yes | No | No | Yes (select states) | | Birth control | Yes | Limited | Yes | Yes | | Perimenopause / menopause HT | No | Yes | No | No | | PCOS management | No | Partial | No | No | | STI testing and treatment | Yes | No | Yes | Yes | | Thyroid care | No | Yes | No | No | | Insurance billing | No | Some plans | No | Sliding scale | | Fertility / preconception | No | No | No | No |

This table reflects publicly available service descriptions as of the date of this review. Service offerings change. Verify directly with each platform before making decisions.

What Midi Health Does That Hey Jane Does Not

Midi Health focuses explicitly on perimenopause and menopause, offering hormone therapy, PCOS care, and thyroid management. It accepts some insurance plans. For a woman in her 40s or 50s, Midi is the more clinically appropriate starting point for hormonal care, while Hey Jane remains the more direct route for reproductive event-specific needs like abortion or emergency contraception.

What Planned Parenthood Direct Offers

Planned Parenthood's telehealth arm covers overlapping territory with Hey Jane, including medication abortion in select states and contraception, and operates on a sliding-scale fee structure that may be more accessible for lower-income women. The geographic restrictions are similar.

Real Patient Considerations: Cost, Access, and Privacy

Hey Jane's cash-pay model means no insurance claim, which some women value for privacy reasons. The cost of approximately $249 to $349 for medication abortion is lower than many in-clinic procedures, but it is not negligible. For a woman earning minimum wage, that may represent multiple days of net income.

Data from the Guttmacher Institute show that cost-related delays in abortion care increase the likelihood of needing a more complex or later procedure, with associated higher costs and risks. A telehealth model that charges cash without sliding-scale options may inadvertently contribute to this dynamic for some patients.

Privacy considerations are real. A mailed package from a telehealth pharmacy can arrive discreetly, which matters in households where reproductive choices are not safe to disclose. This is a genuine structural advantage of the Hey Jane model for some patients.

Clinical Accuracy of Hey Jane's Core Protocol

The mifepristone-misoprostol regimen Hey Jane uses aligns with current evidence. A 2020 ACOG practice bulletin recommends mifepristone 200 mg orally followed by misoprostol 800 mcg buccally 24 to 48 hours later for gestations through 70 days. This is the protocol Hey Jane follows.

As the WomanRx clinical reviewer, Elena Vasquez, MD, notes: "The mifepristone regimen Hey Jane uses is clinically sound. My concern is not the protocol itself but the follow-up infrastructure. Medication abortion at home requires clear instructions on when to seek emergency care, reliable access to follow-up confirmation of completion, and a pathway to aspiration if needed. Patients should ask Hey Jane directly, before starting the process, exactly how those components are handled in their specific state."

This is not a criticism unique to Hey Jane. It applies to all telehealth abortion services. The clinical protocol being correct is necessary but not sufficient; what happens at the edges of the normal course of treatment matters equally.

FAQ